Marubeni Corporation (hereinafter, “Marubeni”) has concluded a Share Purchase Agreement with Sumitomo Pharma Co., Ltd. (hereinafter, “Sumitomo Pharma”) to acquire shares in a newly established company (hereinafter, the “New Company”) that will take over Sumitomo Pharma’s pharmaceutical sales business*1 in Asia*2 through a simplified absorption - type company split*3 (hereinafter, “this transaction”). Marubeni will acquire 60% of the issued shares of the New Company for approximately 45 billion yen.*4 

The pharmaceutical market in Asia, where the New Company is operating, is expected to continue to grow at a high rate in the long term due to population growth, aging, and economic development. Marubeni will take over the pharmaceutical supply system, track record, and trust that Sumitomo Pharma has built up over the years and will contribute to local communities by improving the access to medicines in pharmaceutical areas other than drug discovery.

Marubeni has positioned its pharmaceutical-related business as one of the next-generation businesses in demand in countries around the world and has built a pharmaceutical sales business that handles more than 10,000 products, mainly in China, the Middle East, and Africa. Going forward, Marubeni will position the New Company as Marubeni's pharmaceutical strategic platform and will work to expand its products and the target regions in order to deliver needed products to patients around the world. This will enable Marubeni to grow its pharmaceutical-related business, with sales anticipated to reach more than 100 billion yen by FY2029.

In its Mid-Term Management Strategy (GC2027), Marubeni is focusing on Strategic Platform Investments (businesses with “Growth Domains x High Added Value x Scalability”). In this investment, Marubeni will establish and strengthen a new platform based on the knowledge and track record it has built up in the pharmaceutical sales business, thereby meeting the needs of various patients and creating high added value in the growing pharmaceutical market. In addition, by continuously growing the business through the expansion of the products handled and its target regions, Marubeni aims to contribute to solving global medical issues and increase its corporate value.

*1 Business conducted by Sumitomo Pharma’s wholly owned subsidiaries Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd., along with their subsidiaries.
*2 China, Taiwan, Hong Kong, and Southeast Asian countries 
Reference: Revenue for the fiscal year ending March 2025: 45.8 billion yen, Core segment profit: 23.1 billion yen (Source: Sumitomo Pharma’s Financial Forecasts for the fiscal year ending March 2025, Segment Information)
*3 Acquired through Marubeni Global Pharma Corporation, a wholly owned subsidiary of Marubeni, after completing the necessary procedures, including obtaining approvals from various countries.
*4 Marubeni and Sumitomo Pharma have an option for Marubeni to acquire the remaining 40% stake held by Sumitomo Pharma for approximately 27 billion yen after 2029 in accordance with the terms and conditions set forth in the Shareholders Agreement. However, the actual acquisition price will be determined after adjusting the price based on the Shareholders Agreement.

The New Company Overview
Company Name:	Marubeni Pharmaceuticals Corporation (tentative name)
Head Office:	Japan
Establishment:	April 2025 (scheduled)
Representative:	To be decided
Main Business:	Manufacturing and sales of pharmaceuticals and others.
Sumitomo Pharma (China) Co., Ltd. Overview
Company Name:	Sumitomo Pharma (China) Co., Ltd.
Head Office:	7F, Room A, Zhonghai International Center, No. 1, 838 South Huangpu Road, Huangpu District, Shanghai
Establishment:	2022
Representative:	Yoshitaka Koketsu
Main Business:	Holding companies, management of local subsidiaries, etc.
Sumitomo Pharma Asia Pacific Pte. Ltd. Overview
Company Name:	Sumitomo Pharma Asia Pacific Pte. Ltd.
Head Office:	3 Fraser Street, #07-28 DUO Tower, Singapore 189352
Establishment:	2013
Representative:	Hiroyuki Uemukai
Main Business:	Import, purchase, and sale of pharmaceuticals
Sumitomo Pharma Overview
Company Name:	Sumitomo Pharma Co., Ltd.
Head Office:	2-6-8 Doshomachi, Chuo-ku, Osaka
Establishment:	1897
Representative:	Toru Kimura
Main Business:	Manufacturing and sales of medical drugs, etc.
Website:	https://www.sumitomo-pharma.com/
Marubeni Global Pharma Overview
Company Name:	Marubeni Global Pharma Corporation
Head Office:	1-4-2 Otemachi, Chiyoda-ku, Tokyo
Establishment:	2021
Representative:	Eisuke Kamide
Main Business:	Holding company for investments in pharmaceutical and medical device related businesses